论文部分内容阅读
目的探讨局部中晚期鼻咽癌组织DNA修复基因ERCC1、hMLH1的蛋白表达水平与调强放疗(IMRT)治疗敏感性的关系。方法纳入50例局部中晚期鼻咽癌初治患者,应用免疫组化检测在接受IMRT前ERCC1、hMLH1蛋白的表达情况,分析ERCC1、hMLH1表达水平与鼻咽癌临床特征、IMRT疗效的相互关系,及其对鼻咽癌患者接受IMRT后生存期的影响。结果 ERCC1、hMLH1表达水平与复发、转移有关,复发、转移组的ERCC1、hMLH1阳性表达率明显低于无复发、转移组(2=6.649、2=5.880,均P<0.05),而与年龄、性别、T分期、N分期及临床分期无关;ERCC1、hMLH1的阳性表达率与IMRT放疗敏感性呈负相关(rs=-0.352、rs=-0.376,均P<0.05);ERCC1、hMLH1阳性表达组生存期少于阴性组(P<0.05)。结论 ERCC1、hMLH1蛋白表达水平与IMRT敏感性呈负相关,治疗前可根据ERCC1、hMLH1蛋白的表达水平评估局部中晚期鼻咽癌组织IMRT敏感性。
Objective To investigate the relationship between the expression of ERCC1 and hMLH1 protein and the sensitivity of IMRT in locally advanced nasopharyngeal carcinoma. Methods Fifty patients with locally advanced nasopharyngeal carcinoma were enrolled in this study. The expressions of ERCC1 and hMLH1 protein were detected by immunohistochemistry. The relationship between the expression of ERCC1 and hMLH1 and the clinical features of nasopharyngeal carcinoma and the efficacy of IMRT were analyzed. And its impact on the survival of patients with nasopharyngeal carcinoma after receiving IMRT. Results The positive rates of ERCC1 and hMLH1 expression in ERCC1 and hMLH1 group were significantly higher than those in non-recurrence and metastasis group (2 = 6.649, 2 = 5.880, all P <0.05) Age, sex, T stage, N stage and clinical stage. The positive rates of ERCC1 and hMLH1 were negatively correlated with IMRT radiosensitivity (rs = -0.352, rs = -0.376, all P <0.05) Survival of the expression group less than the negative group (P <0.05). Conclusions The expression of ERCC1 and hMLH1 protein is negatively correlated with IMRT sensitivity. Before treatment, the sensitivity of IMRT in locally advanced and advanced nasopharyngeal carcinoma can be evaluated according to the expression of ERCC1 and hMLH1 protein.